Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes

Table 3 The main plasma pharmacokinetic parameters of bufalin after intravenous administration of bufalin entity, bufalin-loaded liposomes, and bufalin-loaded PEGylated liposomes in rats (n = 6)

Parameters (unit)	Bufalin entity	Bufalin-loaded liposomes	Bufalin-loaded PEGylated liposomes
AUC_(0–t) (ng/(mL min))	25,012.0 ± 2246.3	57,137.5 ± 1453.1**	138,046.0 ± 2771.8**
AUC_(0–∞) (ng/(mL min))	25,334.3 ± 2243.9	57,751.9 ± 1554.0^**	139,157.8 ± 2984.1^**
MRT_(0–t) (min)	29.74 ± 1.39	69.3 ± 2.0^**	138.1 ± 3.3^**
MRT_(0–∞) (min)	33.3 ± 2.3	73.28 ± 2.8^**	142.9 ± 3.7^**
T _1/2z (min)	40.5 ± 10.6	54.4 ± 3.3^*	87.8 ± 7.8^**
V _z/F (L/kg)	0.003 ± 0.001	0.001 ± 0.0008^**	0.0002 ± 0.0004^**
C _max (ng/mL)	1326.6 ± 24.5	1254.0 ± 16.6^**	1071.3 ± 36.3^**

AUC _(0–t) area under the curve from 0 to t, AUC _(0–∞) area under the curve from 0 to ∞, MRT _(0–t) mean retention time from 0 to t, MRT _(0–∞) mean retention time from 0 to ∞; T _1/2z half-life, V _z/F volume of distribution, C _max peak concentration
*P < 0.05, **P < 0.01 compared with bufalin entity group